GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCell Pharma AB (OSTO:NXTCL) » Definitions » Beneish M-Score

NextCell Pharma AB (OSTO:NXTCL) Beneish M-Score : -3.30 (As of May. 24, 2024)


View and export this data going back to 2017. Start your Free Trial

What is NextCell Pharma AB Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.3 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for NextCell Pharma AB's Beneish M-Score or its related term are showing as below:

OSTO:NXTCL' s Beneish M-Score Range Over the Past 10 Years
Min: -6.63   Med: -0.83   Max: 5.34
Current: -3.3

During the past 9 years, the highest Beneish M-Score of NextCell Pharma AB was 5.34. The lowest was -6.63. And the median was -0.83.


NextCell Pharma AB Beneish M-Score Historical Data

The historical data trend for NextCell Pharma AB's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextCell Pharma AB Beneish M-Score Chart

NextCell Pharma AB Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only -0.69 -0.82 -1.68 -1.33 5.34

NextCell Pharma AB Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.56 0.37 5.34 -6.63 -3.30

Competitive Comparison of NextCell Pharma AB's Beneish M-Score

For the Biotechnology subindustry, NextCell Pharma AB's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NextCell Pharma AB's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NextCell Pharma AB's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where NextCell Pharma AB's Beneish M-Score falls into.



NextCell Pharma AB Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of NextCell Pharma AB for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1303+0.528 * -3.0743+0.404 * 1.5112+0.892 * 1.7745+0.115 * 1.1653
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0+4.679 * 0.08945-0.327 * 1.8981
=-3.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Feb24) TTM:Last Year (Feb23) TTM:
Total Receivables was kr17.95 Mil.
Revenue was 2.334 + 4.246 + 2.83 + 3.04 = kr12.45 Mil.
Gross Profit was -0.423 + 1.579 + 0.113 + 0.23 = kr1.50 Mil.
Total Current Assets was kr49.13 Mil.
Total Assets was kr70.54 Mil.
Property, Plant and Equipment(Net PPE) was kr13.41 Mil.
Depreciation, Depletion and Amortization(DDA) was kr0.45 Mil.
Selling, General, & Admin. Expense(SGA) was kr0.00 Mil.
Total Current Liabilities was kr11.10 Mil.
Long-Term Debt & Capital Lease Obligation was kr0.00 Mil.
Net Income was -10.093 + -9.796 + -8.569 + -10.916 = kr-39.37 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = kr0.00 Mil.
Cash Flow from Operations was -10.178 + -9.959 + -13.16 + -12.387 = kr-45.68 Mil.
Total Receivables was kr8.95 Mil.
Revenue was 2.107 + 2.137 + 1.159 + 1.613 = kr7.02 Mil.
Gross Profit was -1.114 + -0.113 + -1.334 + -0.036 = kr-2.60 Mil.
Total Current Assets was kr87.33 Mil.
Total Assets was kr106.60 Mil.
Property, Plant and Equipment(Net PPE) was kr11.27 Mil.
Depreciation, Depletion and Amortization(DDA) was kr0.44 Mil.
Selling, General, & Admin. Expense(SGA) was kr5.67 Mil.
Total Current Liabilities was kr8.83 Mil.
Long-Term Debt & Capital Lease Obligation was kr0.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(17.946 / 12.45) / (8.947 / 7.016)
=1.441446 / 1.275228
=1.1303

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(-2.597 / 7.016) / (1.499 / 12.45)
=-0.370154 / 0.120402
=-3.0743

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (49.129 + 13.41) / 70.542) / (1 - (87.332 + 11.265) / 106.6)
=0.11345 / 0.075075
=1.5112

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=12.45 / 7.016
=1.7745

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.442 / (0.442 + 11.265)) / (0.449 / (0.449 + 13.41))
=0.037755 / 0.032398
=1.1653

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 12.45) / (5.666 / 7.016)
=0 / 0.807583
=0

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 11.095) / 70.542) / ((0 + 8.833) / 106.6)
=0.157282 / 0.082861
=1.8981

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-39.374 - 0 - -45.684) / 70.542
=0.08945

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

NextCell Pharma AB has a M-score of -3.30 suggests that the company is unlikely to be a manipulator.


NextCell Pharma AB Beneish M-Score Related Terms

Thank you for viewing the detailed overview of NextCell Pharma AB's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


NextCell Pharma AB (OSTO:NXTCL) Business Description

Traded in Other Exchanges
Address
Karolinska Institutet Science Park, Halsovagen 7, Huddinge, SWE, 14157
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.

NextCell Pharma AB (OSTO:NXTCL) Headlines

No Headlines